Literature DB >> 2071361

Treatment of progressive supranuclear palsy with methysergide. A clinical study.

G Di Trapani1, P Stampatore, A La Cara, A Azzoni, M L Vaccario.   

Abstract

We present a clinical study of a patient aged 69 years with a clinical history of severe difficulty in walking and voluntary conjugate eye movement reduction in sideways glance and absence in vertical gaze. These symptoms led to diagnosis of Parkinson disease and treatment with L-Dopa + anticholinergics drugs. The treatment with antiparkinsonian drugs was suspended and no change in his clinical condition resulted. Methysergide therapy was initiated and the patient's response was monitored by video recording. On the basis of our experience and the data reported in the literature we believe that methysergide therapy affords some relief of symptoms in patients suffering from PSP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2071361     DOI: 10.1007/BF02337027

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  14 in total

1.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

2.  [Sleep study of progressive supranuclear paralysis].

Authors:  J L Perret; M Jouvet
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1980-08

3.  Methysergide in progressive supranuclear palsy.

Authors:  A S Duncombe; A J Lees
Journal:  Neurology       Date:  1985-06       Impact factor: 9.910

4.  Amitriptyline in the management of progressive supranuclear palsy.

Authors:  J N Kvale
Journal:  Arch Neurol       Date:  1982-06

5.  Treatment of progressive supranuclear palsy with tricyclic antidepressants.

Authors:  G C Newman
Journal:  Neurology       Date:  1985-08       Impact factor: 9.910

6.  Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents.

Authors:  R D Rafal; R J Grimm
Journal:  Neurology       Date:  1981-12       Impact factor: 9.910

7.  Progressive supranuclear palsy, computed tomography, and response to antiparkinsonian drugs.

Authors:  S Haldeman; J W Goldman; J Hyde; H F Pribram
Journal:  Neurology       Date:  1981-04       Impact factor: 9.910

8.  Progressive supranuclear palsy 1979: an overview.

Authors:  A Brusa; G L Mancardi; O Bugiani
Journal:  Ital J Neurol Sci       Date:  1980-10

9.  Bromocriptine in parkinsonism. A long-term study.

Authors:  A J Lees; S Haddad; K M Shaw; L J Kohout; G M Stern
Journal:  Arch Neurol       Date:  1978-08

10.  Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide.

Authors:  G W Paulson; H W Lowery; G C Taylor
Journal:  Eur Neurol       Date:  1981       Impact factor: 1.710

View more
  4 in total

Review 1.  Progressive supranuclear palsy.

Authors:  H U Rehman
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

2.  Sleep Disorders in Atypical Parkinsonism.

Authors:  Sabra M Abbott; Aleksandar Videnovic
Journal:  Mov Disord Clin Pract       Date:  2014-06-01

Review 3.  A Review of Treatment Options for Progressive Supranuclear Palsy.

Authors:  Maria Stamelou; Günter Höglinger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

Review 4.  Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.

Authors:  Brent Bluett; Alexander Y Pantelyat; Irene Litvan; Farwa Ali; Diana Apetauerova; Danny Bega; Lisa Bloom; James Bower; Adam L Boxer; Marian L Dale; Rohit Dhall; Antoine Duquette; Hubert H Fernandez; Jori E Fleisher; Murray Grossman; Michael Howell; Diana R Kerwin; Julie Leegwater-Kim; Christiane Lepage; Peter Alexander Ljubenkov; Martina Mancini; Nikolaus R McFarland; Paolo Moretti; Erica Myrick; Pritika Patel; Laura S Plummer; Federico Rodriguez-Porcel; Julio Rojas; Christos Sidiropoulos; Miriam Sklerov; Leonard L Sokol; Paul J Tuite; Lawren VandeVrede; Jennifer Wilhelm; Anne-Marie A Wills; Tao Xie; Lawrence I Golbe
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.